Previous Article | Next Article 
Journal of Virology, August 2001, p. 7528-7542, Vol. 75, No. 16
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.16.7528-7542.2001
Vaccinia Virus F13L Protein with a Conserved Phospholipase
Catalytic Motif Induces Colocalization of the B5R Envelope
Glycoprotein in Post-Golgi Vesicles
Matloob
Husain and
Bernard
Moss*
Laboratory of Viral Diseases, National
Institute of Allergy and Infectious Diseases, National Institutes
of Health, Bethesda, Maryland
Received 23 February 2001/Accepted 8 May 2001
 |
ABSTRACT |
The wrapping of intracellular mature vaccinia virions by modified
trans-Golgi or endosomal cisternae to form intracellular enveloped virions is dependent on at least two viral proteins encoded
by the B5R and F13L open reading frames. B5R is a type I integral
membrane glycoprotein, whereas F13L is an unglycosylated, palmitylated protein with a motif that is conserved in a superfamily of
phospholipid-metabolizing enzymes. Microscopic visualization of the
F13L protein was achieved by fusing it to the enhanced green
fluorescent protein (GFP). F13L-GFP was functional when expressed by a
recombinant vaccinia virus in which it replaced the wild-type F13L gene
or by transfection of uninfected cells with a plasmid vector followed
by infection with an F13L deletion mutant. In uninfected or infected
cells, F13L-GFP was associated with Golgi cisternae and post-Golgi
vesicles containing the LAMP 2 late endosomal-lysosomal marker.
Association of F13L-GFP with vesicles was dependent on an intact
phospholipase catalytic motif and sites of palmitylation. The B5R
protein was also associated with LAMP2-containing vesicles when
F13L-GFP was coexpressed, but was largely restricted to Golgi cisternae
in the absence of F13L-GFP or when the F13L moiety was mutated. We
suggest that the F13L protein, like its human phospholipase D homolog,
regulates vesicle formation and that this process is involved in
intracellular enveloped virion membrane formation.
 |
INTRODUCTION |
Poxviruses are large, enveloped DNA
viruses that replicate within the cytoplasm of vertebrate or
invertebrate cells (38). Vaccinia virus, a member of the
Orthopoxvirus genus, is the best-characterized poxvirus and
has served as the vaccine for smallpox and as a widely used expression
vector (37). The double-stranded DNA genome of vaccinia
virus contains nearly 200,000 bp and approximately 200 functional open
reading frames (ORFs) (17). The initial steps in vaccinia
virus morphogenesis involve the formation of crescent membranes that
enclose granular viroplasm to form spherical immature virions, which
develop into brick-shaped, infectious intracellular mature virions
(IMV) (8, 20, 27, 36, 57). Some of the IMV are wrapped
with an additional double membrane derived from trans-Golgi
or late endosomal cisternae (25, 53, 61) to form the
intracellular enveloped virions (IEV). The microtubule cytoskeleton is
involved in the formation and movement of both IMV and IEV (43,
51, 66). At the cell periphery, the outermost viral membrane
fuses with the plasma membrane to form extracellular virions. The
particles called cell-associated enveloped virions (CEV) that remain
attached to the cell and those called extracellular enveloped virions
(EEV) that are shed into the medium promote cell-to-cell and long-range
spread, respectively (4, 41). Cell-to-cell spread is
facilitated by the attachment of actin tails to the IEV or CEV, leading
to the formation of virus-tipped microvilli (7, 15, 58,
68).
The membrane-wrapping events that form IEV have been the subject of
numerous investigations. Proteins encoded by seven viral genes have
been identified as specific components of IEV, CEV, or EEV membranes.
Five of these, A33R, A34R, A36R, A56R, and B5R, are
glycoproteins, whereas F12L and F13L are unglycosylated
(11, 13, 28, 40, 42, 48, 54, 64, 72). Recent studies indicated that the A36R protein is present only in the outer IEV membrane, which is not retained on extracellular virions
(64). Deletion of the gene encoding any of the seven
proteins except A56R produces a small-plaque phenotype. The
membrane-wrapping step is inhibited in cells infected with F13L and
B5R deletion mutants (3, 14, 67), whereas later steps,
including actin tail formation, are blocked when A33R, A34R, or A36R is
not expressed (46, 50, 68, 71). Physical interactions
among the A33R, A34R, A36R, and B5R proteins have been reported
(49, 70).
The two proteins, B5R and F13L, required for membrane wrapping are very
different structurally and functionally. B5R is a 42-kDa type I
integral membrane component of the EEV (13, 28). Several
studies with infected cells showed that removal or replacement of
either the lumenal domain or the cytoplasmic tail of B5R had no effect
on the incorporation of the mutated protein into EEV (23, 29, 33,
35). In the absence of other viral proteins, the B5R protein was
targeted to Golgi cisternae (29, 34, 65). Under these
conditions, Golgi membrane localization was dependent on the
transmembrane domain and enhanced by plasma membrane retrieval signals
in the cytoplasmic tail (65).
The 42-kDa F13L protein, sometimes called p37 because of its apparent
mobility as a 37-kDa protein on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), is the most abundant component of the
EEV envelope (25, 26). The resistance of EEV-associated F13L protein to protease digestion suggested that it was present on the
inner surface of the EEV envelope (54). In infected cells, the F13L protein was localized on trans-Golgi and IEV
membranes (25, 53). The protein is modified by
palmitylation of cysteines 185 and 186, which mediates hydrophobicity
and membrane association (22, 24, 25, 54). Nonpalmitylated
F13L protein, expressed by a transfection-infection protocol, exhibited
diffuse cytoplasmic staining (21). There was juxtanuclear
and diffuse cytoplasmic F13L immunostaining in a stably transfected
rabbit kidney cell line that was capable of rescuing an F13L deletion
mutant (5), but only diffuse immunostaining when F13L was
expressed by a Semliki Forest virus vector (34). In both
cases, the authors attributed poor intracellular localization of the
F13L protein to a partial defect in palmitylation or the absence of
other viral proteins.
The role of the F13L protein in membrane wrapping is not understood.
However, F13L contains variant HKD (His-Lys-Asp) motifs that are
conserved in a superfamily of phospholipases and phospholipid synthases
(30, 44, 60), and there has been a report of lipase activity associated with recombinant F13L protein (1).
Furthermore, mutant vaccinia viruses with substitutions of either the
conserved Lys or Asp exhibited wrapping defects that inhibited IEV
formation (47, 60). These results are intriguing because
phospholipase D regulates the budding of vesicles from
trans-Golgi membranes (2, 6, 16, 31, 55, 56,
59).
In the present study we investigated the localization of the F13L and
B5R proteins in post-Golgi vesicles. Visualization of the F13L protein
was achieved by fusing it to the enhanced green fluorescent protein
(GFP). GFP is particularly suitable as a fluorescent reporter because
of its rapid folding and compact structure (63). GFP
linked to either the vesicular stomatitis virus G protein or the
vaccinia virus B5R protein did not interfere with their normal membrane
localization and transport in transfected cells (45, 65).
Moreover, a recombinant virus in which B5R-GFP replaced B5R had a
normal phenotype (66).
Similarly, we show here that F13L-GFP is functional whether
expressed by a recombinant vaccinia virus in which it replaced the
wild-type F13L gene or by transfection of uninfected cells with a
plasmid vector followed by infection with an F13L deletion mutant. In
both uninfected and infected cells, we found that F13L-GFP containing
an intact phospholipase motif was associated with Golgi cisternae and
vesicles containing a late endosomal-lysosomal marker and induced
vesicle colocalization of the B5R glycoprotein.
 |
MATERIALS AND METHODS |
Cells and viruses.
HeLa, RK-13, and BSC-1 cells were grown
in Dulbecco's modified Eagle's medium or Eagle's modified medium
supplemented with 10% fetal bovine serum (FBS) at 37°C with 5%
CO2. The mutant vF13L
, previously referred to as vRB12
(3), has most of the F13L gene replaced with the
Escherichia coli xanthine guanine phosphoribosyltransferase (gpt) gene. Recombinant vF13L-GFP, constructed in this
study, contains the GFP coding sequence at the C terminus of the F13L ORF. For virus titration and analysis of plaque size, infected BSC-1
monolayers were fixed and stained with 0.1% crystal violet in 20% ethanol.
Plasmid construction.
The oligonucleotide primers used to
generate PCR products are listed below with restriction endonuclease
cleavage sites in italics and the F13L start codon, termination
codon, and point mutations in bold: F13L-LF-F,
TATTATTATCGGTTTACGGATGAAAAAT; F13L-LF-R, TTCAAATGTTGTTAAATGATCGGATCT; F13L-RF-F,
GCGGCCGCTTAAAAATTTAAAAAAAAGAAAATAGAGACG; F13L-RF-R, GGATCCCGGTAACACATCAATTTCGGG;
F13L-UF, TATAGAAATAGACGAAGATGACATCATGG; F13L-DF,
GCCTTCTTCATTTCGTGCCAA; F13L-463,
CCGCTGGCCACAGATCTTCGTAG; GFP-265,
CTCCTGGACGTCGCCTTCGGG; F13L-K314R-F, CAGAATAATACAAGATTGTTGATAGTCGACGACG AA;
F13L-K314R-R, GACTATCAACAATCTTGTATTATTCTGAAT;
F13L-D319E-F, TTGTTGATAGTCGAAGACGAATATGTTCAT; F13L-D319E-R,
AACATATTCGTCTTCGACTATCAACAATTTTGT; F13L-1,
ATGTGGCCATTTGCATCGGTA CCT; F13L-C185S-F,
GCGGCTTCTTGTTTGCCAGTTAGCAC; F13L-C185S-R,
GCAAACAAGAAGCCGCAGAGCA; F13L-C186S-F,
GCGGCTTGTTCTTTGCCAGTTAGCAC; F13L-C186S-R,
GCAAAGAACAAGCCGCAGAGCA; and F13L-937,
AACATATTCGTCGTCGACTATCAACAATTTTGT. Platinum PCR supermix and
PCR Supermix High Fidelity (Gibco) were used to amplify DNA fragments.
PCR products were separated by electrophoresis in a 0.8 to 1.2% low-
or high-melting-point agarose (Gibco) gel. Portions of gel with the
desired DNA fragments were excised and eluted with 10 mM Tris (pH 8.0)
using a Qiaex II gel extraction kit (Qiagen).
PCR was used to add an NcoI site to the 3' end of the F13L
ORF in plasmid pSG5-F13L (29) so that an
NcoI-BamHI fragment containing GFP from plasmid
pCDM8 could be ligated in frame to produce pSG5-F13LGFP (abbreviated as
pF13L-GFP).
For making the recombinant virus expressing F13L-GFP, DNA segments of
approximately 600 bp on either side of the F13L ORF
were amplified by
PCR using the F13L-LF-F/F13L-LF-R and F13L-RF-F/F13L-RF-R
primer pairs
and vaccinia virus WR genomic DNA as the template.
PCR fragments were
cloned into plasmid pGEM-T-easy and sequenced.
EcoRI-
KpnI left-flank DNA fragment,
NotI-
BamHI right-flank DNA
fragment from
pGEM-T-easy, and
KpnI-
NotI F13L-GFP fragment from
plasmid pF13L-GFP were inserted at the
EcoRI and
BamHI sites of
plasmid pGEM7 (Promega) by four-fragment
ligation, yielding plasmid
pGF13L. The presence of all the three DNA
fragments in plasmid
pGF13L was confirmed by a series of restriction
endonuclease digestions.
Point mutations in the F13L coding sequence
were introduced by
standard two-stage PCR. To construct
pF13L(K314R)-GFP, in which
Lys was replaced with Arg, and
pF13L(D319E)-GFP, in which Asp
was replaced with Glu, PCR fragments
containing a one-base mutation
for each construct were amplified from
plasmid pF13L-GFP using
primer pairs F13L-463/F13L-K314R-R and
F13L-K314R-F/GFP-265, and
pairs F13L-463/F13L-D319E-R and
F13L-D319E-F/GFP-265. These fragments
were joined by a second PCR using
primer pair F13L-463/GFP-265
and cloned in plasmid pGEM-T-Easy, and the
mutation was confirmed
by sequencing. Plasmid pF13L-GFP had more than
one
NcoI site,
so it was digested with restriction enzymes
NotI and
SpeI to release
a 1,157-bp fragment that
was subsequently digested with
NcoI to
release a 423-bp
SpeI-
NcoI fragment and a 734-bp
NcoI-
NotI GFP
coding sequence.
SpeI-
NcoI fragments containing the point mutation
from pGEM-T-Easy and
NcoI-
NotI GFP fragment were
ligated together
with plasmid pF13L-GFP previously cleaved with
SpeI and
NotI.
Similarly, point mutations
F13L(C185S)-GFP and F13L(C186S)-GFP,
in which the Cys residues at
positions 185 and 186, respectively,
were changed to Ser, were
introduced by PCR. The PCR fragments
were amplified from pF13LGFP using
primer pairs F13L-1/F13L-C185S-R
and F13L-C185S-F/F13L-937 and pairs
F13L-1/F13L-C186S-R and F13L-C186S-F/F13L-937
and joined by a second
PCR using primer pair F13L-1/F13L-937.
Second PCR products were
digested with
KpnI and
SpeI to release
a 674-bp
fragment and cloned in pF13L-GFP that had been cleaved
with
KpnI and
SpeI. The final constructs were
sequenced to confirm
mutations using primer F13L-937. PCR fragments
cloned in plasmid
pGEM-T-Easy were sequenced using M13 forward and
reverse primers
(Promega).
Restriction digestion of PCR fragments and plasmids was routinely
carried out at 37°C for ~20 h and 3 to 4 h, respectively.
Ligations were done at 4°C overnight. All plasmids for
cloning
and sequencing were prepared using the Wizard DNA purification
system
(Promega).
Construction of vF13L-GFP.
HeLa cells were infected with
vF13L
and immediately transfected with plasmid pGF13L. After 3 days
at 37°C, cells were harvested, and the lysate was analyzed by plaque
assay on BSC-1 cells. After 2 days, the plates were examined with a
fluorescence microscope, and large green plaques were picked, plaque
purified, and amplified as described (12).
Antibodies.
A Golgi sampler kit containing mouse monoclonal
antibodies (MAbs) to marker proteins of cis- and
trans-Golgi compartments and EEA1 was purchased from
Transduction Laboratories. Rabbit anti-
-COP polyclonal antibody was
purchased from Affinity Bioreagent Inc. Secondary-antibody conjugates
were purchased from Jackson ImmunoResearch Laboratories. Rabbit
polyclonal antibodies recognizing full-length GFP and mouse anti-GFP
MAb were purchased from Clonetech Laboratories and Covance Co.,
respectively. The 192C rat MAb against B5R has been described
(53). Mouse anti-LAMP2 MAb was a kind gift from Thomas
August, Johns Hopkins School of Medicine, Baltimore, Md.
Transfection and infection.
HeLa cells were transfected with
plasmids using Lipofectamine (LF) 2000 (Gibco-BRL) according to the
instructions of the manufacturer. Briefly, cells were grown on glass
coverslips (22 by 22 mm) till they reached 80% confluence. Routinely,
10 µg of LF 2000 and 2 µg of DNA were diluted separately in
Opti-MEM I medium (Gibco-BRL), mixed, and incubated at room temperature
for 20 min. The LF 2000-DNA complex was added to the cells; after
5 h at 37°C, the overlay was replaced with fresh Opti-MEM I, and
the incubation was continued for a total of 24 h. Plasmid DNA for
transfection was prepared using Qiagen plasmid midipreparation kit. For
infection, virus stocks were diluted in the culture medium with 2.5%
FBS and added to the cell monolayers in the wells or coverslips. After
2 h of incubation at 37°C, the virus inoculum was replaced with
fresh culture medium (2.5% FBS) and incubated for a further 17 to
18 h.
Immunoblotting and immunoprecipitation.
For immunoblotting,
transfected or virus-infected HeLa cells were harvested and washed once
with phosphate-buffered saline (PBS). The cells were resuspended in
sample buffer (62.5 mM Tris-HCl [pH 6.8], 2% [wt/vol] SDS, 0.02%
[wt/vol] bromophenol blue, 10% [vol/vol] glycerol, and 5%
[vol/vol]
-mercaptoethanol) and heated for 10 min at 95°C.
Proteins were resolved by electrophoresis in an SDS-12%
polyacrylamide gel and transferred to a nitrocellulose membrane.
Protein-free sites of the membrane were blocked by incubation overnight
with 3% (wt/vol) nonfat milk protein in PBS. The membrane was
incubated with mouse anti-GFP MAb, followed by horseradish peroxidase-conjugated anti-mouse immunoglobulin (Ig) antibody, both
diluted in 1% nonfat milk for 1 h at room temperature with constant shaking. The membrane was washed extensively with PBS containing 0.05% (wt/vol) Tween 20 before incubation with each antibody and developed with a chemiluminescence kit (Pierce) according to the manufacturer's procedure.
For immunoprecipitation, transfected or infected HeLa cells were pulse
labeled with 200 or 50 µCi of [
35S]methionine per ml,
respectively, for 2 h at 37°C. Cells were
harvested and lysed in
PBS with three freeze-thaw cycles. An equal
volume of 2×
radioimmunoprecipitation assay (RIPA) buffer (1×
RIPA buffer is 1%
[wt/vol] sodium deoxycholate, 1% [vol/vol] Triton
X-100, 0.2%
[wt/vol] SDS, 150 mM sodium chloride, 50 mM Tris-HCl
[pH 7.4], and
1 mM phenylmethylsulfonyl fluoride) was added to
the cell lysate and
incubated on ice for 15 min. The samples were
then heated at
70°C for 2 min and centrifuged at 10,000 ×
g for
5 min at 4°C. The supernatant was collected, diluted to 0.5 ml
with
water, and incubated with 2.5 µl of rabbit polyclonal anti-GFP
antibody for 2 h on ice. Protein G-Sepharose (40 µl) was added
and incubated at 4°C for 18 h with gentle shaking. The beads
were
washed with 1× RIPA buffer, and proteins were resolved as
described
by SDS-PAGE and visualized by fluorography followed by
autoradiography.
Confocal microscopy.
At 24 h after transfection, the
cells were fixed with cold 4% paraformaldehyde in PBS at room
temperature for 20 min and then permeabilized with 0.2% Triton X-100
in PBS for 5 min at room temperature. The permeabilized cells were
incubated with primary antibodies diluted in 10% FBS in PBS for 1 h, followed by secondary antibody diluted in 10% FBS in PBS for 30 min
at room temperature. For double staining of the proteins, cells were
stained separately with each antibody to minimize the cross-reactivity.
For staining actin filaments, the cells were fixed with 3%
paraformaldehyde in CSB (10 mM MES [morpholineethanesulfonic acid, pH
6.1], 150 mM sodium chloride, 5 mM EGTA, 5 mM glucose, 5 mM
MgCl2 · 6H2O), permeabilized, and
incubated with phalloidin-rhodamine (Molecular Probes) in PBS for 30 min at room temperature. Golgi apparatus was visualized by staining
with mouse anti-p115 MAb unless otherwise stated. Stained cells were
washed extensively with PBS, and coverslips were mounted in 20%
glycerol and sealed with rubber cement. In some experiments, 10 µg of
brefeldin A (BFA) (Sigma) per ml was added to the cells at 24 h
after transfection, and the cells were incubated for an additional 30 min at 37°C and stained as described above. Fluorescence was examined
with a Leica TCS NT inverted confocal microscope, and images were
overlaid by using Adobe Photoshop version 5.0.2.
Immunoelectron microscopy.
RK-13 cells were infected with
vF13L-GFP at a multiplicity of 10 and incubated for 22 h. The
cells were fixed and prepared for immunoelectron microscopy as
described (69). Briefly, cryosections were incubated with
rabbit anti-GFP polyclonal antibody followed by protein A conjugated to
10-nm colloidal gold. Stained cryosections were viewed using a Philips
CM 100 transmission electron microscope.
 |
RESULTS |
Localization and function of F13L-GFP fusion protein during
vaccinia virus infection.
Initial experiments were designed to
determine whether the attachment of GFP to F13L would perturb the
function of the viral protein. We considered that the rescue of a
mutant vaccinia virus with a deleted F13L gene would demonstrate that
the F13L-GFP protein functioned properly. To insert the F13L-GFP gene
into the vaccinia virus genome by homologous recombination, we
constructed a plasmid containing the F13L gene and flanking DNA in
which the GFP coding sequence was appended to the C terminus of
the F13L ORF, leaving the viral transcriptional regulatory
sequences unaltered (Fig. 1A). HeLa
cells were infected with vF13L
, a mutant vaccinia virus that
contains gpt in place of the deleted F13L gene
(3), and transfected with the plasmid carrying the
F13L-GFP chimera. The plaques exhibiting green fluorescence were
similar in size to those of wild-type virus and much larger than those
of vF13L
(Fig. 1B and C). Of five such plaques picked, each was
shown to contain the appropriate 1.9-kbp F13L-GFP ORF by PCR instead of the slightly larger product containing the gpt gene of the
deletion mutant (Fig. 1D). One of these recombinant viruses, named
vF13L-GFP, was plaque picked additional times and amplified to give
titers similar to that of wild-type vaccinia virus. Expression of the F13L-GFP protein was demonstrated by infecting HeLa cells with vF13L-GFP and analyzing the lysate by SDS-PAGE and Western blotting or
by metabolic labeling followed by SDS-PAGE and autoradiography. A major
band with a predicted mass of 64 kDa reacted with antibody to GFP (Fig.
1E).

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 1.
Construction and characterization of a recombinant
vaccinia virus that expresses GFP-tagged F13L protein. (A) Diagram of a
portion of the plasmid transfer vector used for recombination. The GFP
coding sequence was appended in frame to the C-terminal amino acid of
the F13L ORF. Flank 1 and flank 2 represent approximately 600 bp each
of viral DNA on either side of the F13L ORF. (B) Crystal violet-stained
plaques of the F13L deletion mutant vF13L , vF13L-GFP, and wild-type
vaccinia virus strain WR prepared with a methylcellulose overlay.
(C) Visualization of a vF13L-GFP plaque by phase contrast and
fluorescence microscopy. (D) Agarose gel electrophoresis of PCR
products from cells infected with virus from five different recombinant
plaques (lanes 1 to 5) and genomic DNA of vF13L (lane 6) and
wild-type vaccinia virus (lane 7). Oligonucleotide primers flanked the
F13L gene. Lane MW, size markers. (E) SDS-PAGE immunoblot and
autoradiogram of immunoprecipitate of F13L-GFP protein. HeLa cells were
mock infected or infected with vF13L-GFP and harvested after 24 h.
The immunoblot was probed with an anti-GFP mouse MAb. For
immunoprecipitation (IP), the mock-infected or infected cells were
labeled with [35S]methionine for 2 h, and the lysate
was incubated with rabbit anti-GFP polyclonal antibodies, followed by
protein A beads.
|
|
The formation of large plaques by vF13L-GFP suggested that IEV, actin
tails, and CEV had formed. This was confirmed by microscopy.
We
visualized green fluorescent particles in the peripheral regions
of
HeLa cells infected with vF13L-GFP. Some of the particles were
shown to
have actin tails by staining with phalloidin-rhodamine,
indicating that
they were IEV or CEV (Fig.
2A). Direct
evidence
of IEV and CEV formation and the incorporation of the F13L-GFP
fusion protein into their membranes was obtained by immunoelectron
microscopy. Thin sections of vF13L-GFP-infected RK-13 cells were
labeled with rabbit anti-GFP polyclonal antibody followed by a
protein
A-gold conjugate. Gold grains corresponding to GFP were
present on the
outer membranes of IEV (Fig.
2C), whereas no gold
grains were
detected on IMV (Fig.
2B). Thus, the formation of
normal-size plaques,
actin tails, IEV, and CEV and the association
of F13L-GFP with wrapped
virions indicated that the chimeric protein
was functional.

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 2.
Visualization of F13L-GFP by confocal or
electron microscopy in cells infected with vF13L-GFP. (A) HeLa cells
were infected with 1 PFU of vF13L-GFP per cell. After 18 h, the
cells were fixed, permeabilized, stained with
rhodamine-phalloidin, and examined by confocal microscopy. Arrows
point to green fluorescent particles at the tips of red actin tails.
RK13 cells were infected with 10 PFU of vF13L-GFP virus per cell.
After 22 h, the cells were fixed, cryosectioned, and probed with
rabbit anti-GFP polyclonal antibodies followed by protein A conjugated
to 10-nm colloidal gold particles. Electron micrographs show unlabeled
IMV (B) and labeled IEV (C). Arrows point to gold grains.
|
|
Colocalization of F13L-GFP and B5R envelope proteins.
To
facilitate further experiments, we also constructed a plasmid
expression vector that contained the F13L-GFP ORF regulated by a simian
virus 40 promoter instead of a vaccinia virus promoter. Expression of
the 64-kDa fusion protein in uninfected cells was detected by
immunoblotting and immunoprecipitation (data not shown). HeLa cells
were transfected with pF13L-GFP and 24 h later infected with the
vaccinia virus F13L deletion mutant vF13L
to visualize the
intracellular location of the chimeric protein expressed in this
manner. The B5R envelope protein colocalized with F13L-GFP in punctate
structures in the periphery of the cell and in a juxtanuclear region
(Fig. 3, Second row).
Moreover, the pattern was similar to that obtained when cells were
infected with vF13L-GFP (Fig. 3, first row). In contrast, the B5R
protein was predominantly in the juxtanuclear region when
vF13L
-infected cells were not transfected with pF13L-GFP (Fig.
3, fourth row, last panel).

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 3.
Colocalization of F13L-GFP and B5R protein in infected
or transfected cells. First row, HeLa cells were infected with
vF13L-GFP (1 PFU/cell) for 18 h and then fixed,
permeabilized, and stained with anti-B5R MAb followed by
rhodamine-conjugated anti-rat Ig antibody and examined by confocal
microscopy. Second row, HeLa cells were transfected with plasmid
pF13L-GFP; after 24 h, the cells were infected with vF13L (5 PFU/cell) and stained and examined by confocal microscopy as in the
first row. Third row, HeLa cells were cotransfected with pF13L-GFP
and pB5R. After 24 h, the cells were fixed, permeabilized, and
stained. Fourth row, HeLa cells were transfected with pF13L-GFP alone
(left) or pB5R alone (middle) or infected with vF13L alone (right)
and stained and examined by confocal microscopy. Green, GFP; red,
rhodamine; yellow, overlap of green and red.
|
|
The above experiment demonstrated that expression of F13L
was required for the localization of the B5R protein in
peripheral
punctate structures. However, many other viral proteins may
also
have been required, since expression occurred in the context of
a
viral infection. To evaluate this possibility, HeLa cells were
cotransfected with pF13L-GFP and a plasmid expressing B5R (pB5R)
but
were not subsequently infected (Fig.
3, third row). Colocalization
of
B5R and F13L-GFP occurred in the absence of other viral proteins
(Fig.
3, third row). As expected from previous studies, B5R was
largely in
the juxtanuclear region when expressed in uninfected
cells without
F13L-GFP (Fig.
3, fourth row, center panel). The
location of the
F13L-GFP protein in juxtanuclear and punctate
structures, however, was
unaffected by the absence of the B5R
protein (Fig.
3, fourth row, first
panel). Taken together, these
data suggest that the F13L-GFP was
intrinsically capable of localizing
in peripheral punctate as well as
in juxtanuclear structures and
that F13L-GFP induced colocalization of
the B5R
protein.
Intracellular localization of F13L-GFP in the absence of other
viral proteins.
A variety of MAbs were used to characterize the
cellular compartments containing F13L-GFP. The fluorescent F13L-GFP in
the juxtanuclear region overlapped the cis-Golgi proteins
p115 (Fig. 4) and GM130 (data not shown)
as well as p230, a peripheral membrane protein associated with the
cytoplasmic face of the trans-Golgi cisternae (Fig. 4). Much
of the F13L-GFP, however, was in punctate structures. To identify these
structures, we stained the transfected cells with MAbs to LAMP2, a type
1 integral membrane protein that is associated with late endosomes and
lysosomes, and EEA1, a marker for early endosomes. There was more
overlap of green fluorescence with LAMP2 than EEA1 (Fig. 4), suggesting
a greater association of F13L-GFP with late endosomal-lysosomal
vesicles than early endosomes.

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 4.
Colocalization of F13L-GFP with cellular
markers in transfected cells. HeLa cells were transfected with plasmid
pF13LGFP for 24 h and then fixed, permeabilized, and stained with
the indicated MAbs. Transfected HeLa cells were stained with mouse
anti-p115, anti-p230, LAMP2, or EEA1 MAbs followed by
rhodamine-conjugated anti-mouse Ig antibody. Stained cells were then
examined by confocal microscopy. Green, GFP; red, rhodamine; yellow,
overlap of green and red.
|
|
BFA, a fungal metabolite that disrupts the structure and function of
the Golgi cisternae (
9,
32), was used to further
investigate the intracellular locations of F13L-GFP. HeLa cells
were
transfected with pF13L-GFP for 24 h and then treated for
30 min
with BFA. The cells were stained with an MAb to the coatomer
protein

-COP, which rapidly dissociates from the Golgi apparatus
after BFA
treatment (
10). In the absence of BFA, the MAb to

-COP
stained the Golgi complex as well as endoplasmic reticulum-to-Golgi
vesicles (Fig.
5, first
row). Some overlap of

-COP with F13L-GFP
in the Golgi region was
noted (Fig.
5, first row), consistent
with the data above. After BFA
treatment, the

-COP was diffusely
distributed in the cytoplasm,
whereas there was persistence of
vesicles containing F13L-GFP (Fig.
5,
second row). Comparison
of the F13L-GFP in the absence (first row) and
presence (second
row) of BFA, however, did show increased diffuse
staining under
the latter conditions, resulting from the dissociation
of some
F13L-GFP from Golgi membranes. Most strikingly, BFA did not
affect
the colocalization of F13L-GFP with LAMP2 (Fig.
5, third row),
consistent with the association of F13L-GFP with endosomes or
lysosomes. As another control, cells were transfected with a plasmid
expressing B5R alone. As expected, the B5R protein colocalized
with

-COP in the absence of BFA and was dispersed after BFA treatment
(Fig.
5, last two rows).

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of BFA on the localization of
F13L-GFP and B5R protein in transfected cells. HeLa cells were
transfected with pF13L-GFP or pB5R for 24 h. One set of
transfected cells was treated with BFA (10 µg/ml) for 30 min. The
cells were then fixed, permeabilized, and stained with rabbit
anti- -COP polyclonal antibody followed by Texas red-conjugated
anti-rabbit Ig antibody or with LAMP2 MAb followed by
rhodamine-conjugated anti-mouse Ig antibody. Those cells that had been
transfected with pB5R were then stained with rat anti-B5R MAb followed
by fluorescein isothiocyanate (FITC)-conjugated anti-rat Ig antibody.
Cells were analyzed by confocal microscopy. Green, GFP or FITC; red,
Texas red or rhodamine; yellow, overlap of green and red.
|
|
Effect of F13L-GFP on intracellular localization of B5R
protein.
Additional experiments were carried out to determine
whether B5R, when coexpressed with F13L-GFP, also colocalized in
BFA-resistant LAMP2-containing vesicles. First we showed that when B5R
was expressed alone, there was no colocalization with LAMP2 (Fig.
6, first row). When B5R and F13L-GFP were
coexpressed, however, B5R was present in vesicles associated with
F13L-GFP and LAMP2 (Fig. 6, second and third rows). Furthermore, this
association was resistant to BFA (Fig. 6, fourth and fifth rows). These
observations indicated that F13L-GFP was responsible for alterations in
the intracellular localization of B5R.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 6.
Colocalization of B5R protein with LAMP2 in cells
expressing F13L-GFP. HeLa cells were transfected with pB5R alone or
cotransfected with pF13L-GFP and pB5R for 24 h. One set of
cotransfected cells was treated with BFA for 30 min. Cells were fixed,
stained, and examined as described in the legend to Fig. 5. Unmerged
and merged images are labeled with the name of a single protein or the
names of two proteins, respectively. First row: green, FITC; red,
rhodamine; yellow, overlap of green and red. Other rows: green, GFP;
red, rhodamine; white, indodicarbocyanine (Cy5); yellow,
overlap of green and red; purple, overlap of green and white; blue,
overlap of white and red.
|
|
Additional studies were designed to see if colocalization of F13L-GFP,
B5R, and LAMP2 occurred during a productive vaccinia
virus infection.
We therefore stained vF13L-GFP-infected cells
with anti-LAMP2 and
anti-B5R antibodies. Although staining was
less intense under these
conditions, there was colocalization
of F13L-GFP, B5R, and LAMP2 in
punctate structures that could
be endosomal vesicles or IEV membranes
(Fig.
7, first and second
rows). No
colocalization of B5R and LAMP2 in peripheral punctate
structures
occurred when F13L was not expressed in cells infected
with vF13L

(Fig.
7, third row). Thus, F13L was required for colocalization
of B5R
with LAMP2-containing vesicles in both transfected and
infected cells.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 7.
Colocalization of F13L-GFP, B5R, and LAMP2 in
vF13L-GFP-infected cells. HeLa cells were infected with 1 PFU of
vF13L-GFP or vF13L per cell for 18 h and then fixed,
permeabilized, and stained with mouse anti-LAMP2 MAb followed by
rhodamine-conjugated anti-mouse Ig antibody. The cells were then
stained with rat anti-B5R MAb followed by Cy5-conjugated anti-rat Ig
antibody and examined by confocal microscopy. Unmerged and merged
images are labeled with the name of a single protein or the names of
two proteins, respectively. First and second rows: green, GFP; white,
Cy5; red, rhodamine; purple, overlap of green and white; yellow,
overlap of green and red; blue, overlap of white and red. Third row:
green, Cy5; red, rhodamine; yellow, overlap of green and red.
|
|
Effect of mutations in phospholipase catalytic site motif of
F13L-GFP.
We suspected that the localization of the F13L protein
in endosome-like vesicles might require phospholipase activity. To evaluate this possibility, we constructed expression plasmids with
single amino acid substitutions in the conserved active-site phospholipase motif of F13L-GFP. Previous studies had shown that vaccinia virus mutants with F13L(K314R) or F13K(D319E) substitutions in
the putative phospholipase catalytic site behaved like F13L deletion
mutants (47, 60). In those studies, the F13L(K314R) protein was still palmitylated, whereas the F13K(D319E) protein was
insoluble and difficult to analyze. We found that after transfection, F13L(K314R)-GFP localized predominantly in the juxtanuclear Golgi complex, with relatively little fluorescence associated with vesicles or the plasma membrane (Fig. 8, first
row). F13L(D319E)-GFP, however, was distributed throughout the
cytoplasm (Fig. 8, second row), suggesting a general defect in membrane
association that was correlated with decreased partitioning into the
Triton X-114 detergent phase (data not shown). Western blots similar to
the one in Fig. 1E confirmed that the GFP moiety was still associated
with the F13L fusion protein (data not shown). Additional experiments
indicated that the B5R protein also remained predominantly in the
juxtanuclear Golgi region when coexpressed with mutated F13L-GFP (Fig.
8, third and fourth rows). Therefore, the putative catalytic site of
F13L was important for localization of the F13L-GFP and B5R protein.

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 8.
Effect of amino acid substitutions in the
phospholipase active-site motif of F13L-GFP on intracellular
localization. HeLa cells were transfected with pF13L(K314R)-GFP or
pF13L(D319E)-GFP or cotransfected with those plasmids and pB5R. After
24 h, the cells were fixed, permeabilized, and stained with mouse
anti-p115 MAb followed by rhodamine-conjugated anti-mouse Ig antibody
or rat anti-B5R MAb followed by rhodamine-conjugated anti-rat Ig
antibody.
|
|
Effect of mutations in palmitylation site of F13L-GFP.
Palmitylation of the F13L protein occurs at cysteines 185 and 186, and
mutation of the two abrogated Golgi localization of F13L in
virus-infected cells (22). We constructed plasmids that express F13L-GFPs containing a single C185S or C186S mutation. When
transfected alone, F13L(C185S)-GFP was localized primarily in the Golgi
complex while F13L(C186S)GFP was distributed throughout the cell (Fig.
9, first and second rows). The
F13L(C186S)-GFP was expressed to a lower level, as shown by Western
blotting, and exhibited decreased partitioning in the Triton X-114
detergent phase compared to the unmutated F13L-GFP (data not shown).
The B5R protein remained predominantly in the juxtanuclear region when
coexpressed with either of these mutants (Fig. 9, third and fourth
rows).

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 9.
Effect of amino acid substitutions of the
palmitylation sites of F13L-GFP on intracellular localization. HeLa
cells were transfected with pF13L(C185S)-GFP or pF13L(C186S)-GFP or
cotransfected with those plasmids and pB5R for 24 h. Cells were
fixed, permeabilized, stained, and examined by confocal microscopy as
described for Fig. 8.
|
|
 |
DISCUSSION |
The present study concerns the two EEV proteins F13L and B5R,
which are required for the membrane wrapping of IMV to form IEV. To
visualize the F13L protein by confocal microscopy, we expressed an
F13L-GFP fusion protein from a recombinant vaccinia virus or a plasmid
vector. The fluorescent fusion protein was incorporated into IEV and
CEV membranes and rescued a well-characterized F13L deletion mutant
that made tiny plaques and had a defect in wrapping IMV
(3). Having demonstrated the proper function of the
F13L-GFP protein in the context of a virus infection, we analyzed its
distribution in the absence of other viral proteins. Strong fluorescence was obtained in the juxtanuclear region, more peripheral punctate structures, and the plasma membrane. A similar distribution was found using an influenza virus hemagglutinin (HA) epitope-tagged F13L protein (M. Husain, unpublished data). We found that F13L-GFP in
the juxtanuclear region colocalized with the cis- and and
trans-Golgi cisternal membrane markers p115, GM130, and
p230. Many of the punctate structures colocalized with LAMP2, a protein
that enters the endosomal pathway at the trans-Golgi network
and is found in late endosomes and lysosomes (18, 19).
There was less colocalization of F13L-GFP with EEA1, an early endosomal
marker (39), than with LAMP2. As expected for endosomal
localization, the fluorescent F13L-GFP/LAMP2-associated vesicles were
resistant to BFA addition.
The colocalization of the B5R protein with BFA-resistant LAMP2 vesicles
when B5R was coexpressed with F13L-GFP was a notable finding. When the
B5R protein was expressed alone, it was mostly associated with Golgi
cisternal markers and was sensitive to BFA, as anticipated from
previous studies (65). How could the F13L protein alter
the localization of the B5R protein? Previous efforts to detect
physical association of the F13L protein with the B5R or other viral
proteins by immunoprecipitation were unsuccessful using a variety of
lysis conditions (54). Similarly, we could not detect
associations by coimmunprecipitation (M. Husain, unpublished data). An
alternative possibility is that the F13L protein regulates vesicle
formation through its phospholipase activity, analogous to that
reported for phospholipase D (2, 6, 16, 31, 55, 56, 59).
Phospholipase D catalyzes the hydrolysis of phosphatidylcholine to
phosphatidic acid and choline, which induces coatomer binding and
vesicle formation at the trans-Golgi network. By a similar
mechanism, inclusion of the B5R protein into post-Golgi vesicles might
depend on phospholipase activity of F13L rather than a direct physical
association between the two viral proteins. Support for such a
mechanism comes from mutagenesis. Mutation of the conserved Lys-314 in
the phospholipase D active-site motif to Arg did not affect the Golgi
membrane localization of the F13L protein but inhibited its association
and the association of the B5R protein with post-Golgi vesicles. This
result could suggest that the F13L protein, like B5R, is targeted to
the Golgi cisternae but requires phospholipase activity to generate or
associate with post-Golgi vesicles. The F13L-GFP protein with the
conserved Asp-319 changed to Glu was distributed diffusely in the
cytoplasm, suggesting that the mutation affected palmitylation.
Mutation to serine of either of the two Cys residues that become
palmitylated also inhibited the association of F13L-GFP protein and the
B5R protein with post-Golgi vesicles. Golgi localization still occurred
with the Cys-185 mutant but not with the Cys-186 mutant. Importantly,
mutations in both the catalytic motif and the palmitylation sites
blocked IEV formation in infected cells (21, 47, 60). That
the F13L protein actually induces vesicle formation or blocks vesicle
recycling is suggested by the eventual dispersal of much of the Golgi
cisternae by 48 h after transfection with the F13L-GFP expression
vector (M. Husain, unpublished data). A similar disruption of the Golgi
complex occurs late during a productive vaccinia virus infection and
has been attributed to the exhaustive use of Golgi membranes for
wrapping IMV (25). Further studies on the lipase activity
of the F13L protein are needed. Although phospholipase A and C
activities of a recombinant F13L were reported (1),
phospolipase D activity remains to be demonstrated (60).
The F13L protein lacks a signal peptide or a membrane-spanning domain,
and membrane association is dependent on palmitylation (21,
54). Presumably, F13L-GFP associates with the cytoplasmic face
of the Golgi and endosomal vesicles. The fact that single-base substitutions of F13L-GFP can largely restrict it to the Golgi cisternae argues against a trivial explanation for the endosomal location. These static studies, however, do not reveal whether F13L-GFP
goes directly to endosomal vesicles, arrives there via the
trans-Golgi membrane during vesicle formation, and is
internalized by endocytic receptors from the plasma membrane or by some
combination of these mechanisms. The F13L protein has several tyrosine-
and dileucine-based motifs that could be involved in internalization from endocytic receptors or targeting to endosomal compartments (52, 62). Efforts to determine the roles of these motifs
in the localization of F13L-GFP are in progress.
The majority of experiments in this study were carried out using a
simple transfection system in order to dissect out possible roles for
the F13L protein. The vesicles that have been characterized here
contain only two viral proteins and cannot be equivalent to the
cisternal structures that envelop IMV in infected cells. Nevertheless,
there are some correlates between the transfection and infection
systems. For example, in both, the absence of the F13L protein results
in retention of the B5R protein in Golgi cisternae. Moreover, a similar
situation occurs when the F13L protein is mutated in the phospholipase
motif or the palmityl acceptor cysteines. In addition, using confocal
microscopy, we detected colocalization of F13L-GFP, B5R protein, and
LAMP2 in punctate structures in the cytoplasm of infected cells.
Further studies will be needed to confirm or reject the hypothesis that the F13L protein has an enzymatic role in inducing or modifying vesicles that form the IEV membrane.
 |
ACKNOWLEDGMENTS |
We thank members of the Laboratory of Viral Diseases for interest
and assistance. In particular, Brian Ward provided pSG5-F13LGFP and
made many useful suggestions regarding confocal microscopy, Andrea
Weisberg carried out electron microscopy, and Norman Cooper provided tissue culture cells. Much of the work was carried out in
the NIAID imaging facility with the expert guidance of Owen Schwartz. Brian Ward and Jonathan Yewdell made helpful comments regarding the preparation of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: 4 Center Drive,
MSC 0445, NIH, Bethesda, MD 20892-0445. Phone: (301) 496-9869. Fax: (301) 480-1147. E-mail: bmoss{at}nih.gov.
 |
REFERENCES |
| 1.
|
Baek, S.-H.,
J.-Y. Kwak,
S. H. Lee,
T. Lee,
S. H. Ryu,
D. J. Ublinger, and J. D. Lambeth.
1997.
Lipase activities of p37, the major envelope protein of vaccinia virus.
J. Biol. Chem.
272:32042-32049[Abstract/Free Full Text].
|
| 2.
|
Bednarek, S. Y.,
L. Orici, and R. Schekman.
1996.
Traffic COPS and the formation of vesicle coats.
Trends Cell Biol.
6:468-473[CrossRef][Medline].
|
| 3.
|
Blasco, R., and B. Moss.
1991.
Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-dalton outer envelope protein.
J. Virol.
65:5910-5920[Abstract/Free Full Text].
|
| 4.
|
Blasco, R., and B. Moss.
1992.
Role of cell-associated enveloped vaccinia virus in cell-to-cell spread.
J. Virol.
66:4170-4179[Abstract/Free Full Text].
|
| 5.
|
Borrego, B.,
M. M. Lorenzo, and R. Blasco.
1999.
Complementation of P37 (F13L gene) knock-out in vaccinia virus by a cell line expressing the gene constitutively.
J. Gen. Virol.
80:425-432[Abstract].
|
| 6.
|
Chen, Y. G.,
A. Siddhanta,
C. D. Austin,
S. M. Hammond,
T. C. Sung,
M. A. Frohman,
A. J. Morris, and D. Shields.
1997.
Phospholipase D stimulates release of nascent secretory vesicles from the trans-Golgi network.
J. Cell Biol.
138:495-504[Abstract/Free Full Text].
|
| 7.
|
Cudmore, S.,
P. Cossart,
G. Griffiths, and M. Way.
1995.
Actin-based motility of vaccinia virus.
Nature
378:636-638[CrossRef][Medline].
|
| 8.
|
Dales, S., and L. Siminovitch.
1961.
The development of vaccinia virus in Earle's L strain cells as examined by electron microscopy.
J. Biophys. Biochem. Cytol.
10:475-503[Abstract/Free Full Text].
|
| 9.
|
Doms, R. W.,
G. Russ, and J. W. Yewdell.
1989.
Brefeldin A redistributes resident and itinerant Golgi proteins to the enodplasmic reticulum.
J. Cell Biol.
109:61-72[Abstract/Free Full Text].
|
| 10.
|
Donaldson, J. G.,
J. Lippincott-Schwartz,
G. S. Bloom,
T. E. Kreis, and R. D. Klausner.
1990.
Dissociation of a 110-kD peripheral membrane protein from the Golgi apparatus is an early event in brefeldin A action.
J. Cell Biol.
111:2295-2306[Abstract/Free Full Text].
|
| 11.
|
Duncan, S. A., and G. L. Smith.
1992.
Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress.
J. Virol.
66:1610-1621[Abstract/Free Full Text].
|
| 12.
|
Earl, P. L., and B. Moss.
1991.
Generation of recombinant vaccinia viruses, p. 16.17.1-16.17.16.
In
F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 2. Greene Publishing Associates & Wiley Interscience, New York, N.Y.
|
| 13.
|
Engelstad, M.,
S. T. Howard, and G. L. Smith.
1992.
A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope.
Virology
188:801-810[CrossRef][Medline].
|
| 14.
|
Engelstad, M., and G. L. Smith.
1993.
The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence.
Virology
194:627-637[CrossRef][Medline].
|
| 15.
|
Frischknecht, F.,
V. Moreau,
S. Rottger,
S. Gonfloni,
I. Reckmann,
G. Superti-Furga, and M. Way.
1999.
Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling.
Nature
401:926-929[CrossRef][Medline].
|
| 16.
|
Frohman, M. A., and A. J. Morris.
1996.
Rho is only ARF the story: phospholipid signalling.
Curr. Biol.
6:945-947[CrossRef][Medline].
|
| 17.
|
Goebel, S. J.,
G. P. Johnson,
M. E. Perkus,
S. W. Davis,
J. P. Winslow, and E. Paoletti.
1990.
The complete DNA sequence of vaccinia virus.
Virology
179:247-266[CrossRef][Medline].
|
| 18.
|
Gough, N. R., and D. M. Fambrough.
1997.
Different steady state subcellular distributions of the three splice variants of lysosome-associated membrane protein LAMP-2 are determined largely by the COOH-terminal amino acid residue.
J. Cell Biol.
137:1161-1169[Abstract/Free Full Text].
|
| 19.
|
Green, S. A.,
K. P. Zimmer,
G. Griffiths, and I. Mellman.
1987.
Kinetics of intracellular transport and sorting of lysosomal membrane and plasma membrane proteins.
J. Cell Biol.
105:1227-1240[Abstract/Free Full Text].
|
| 20.
|
Grimley, P. M.,
E. N. Rosenblum,
S. J. Mims, and B. Moss.
1970.
Interruption by rifampin of an early stage in vaccinia virus morphogenesis: accumulation of membranes which are precursors of virus envelopes.
J. Virol.
6:519-533[Abstract/Free Full Text].
|
| 21.
|
Grosenbach, D. W., and D. E. Hruby.
1998.
Analysis of a vaccinia virus mutant expressing a nonpalmitylated form of p37, a mediator of virion envelopment.
J. Virol.
72:5108-5120[Abstract/Free Full Text].
|
| 22.
|
Grosenbach, D. W.,
D. O. Ulaeto, and D. E. Hruby.
1997.
Palmitylation of the vaccinia virus 37-kDa major envelope antigen. Identification of a conserved acceptor motif and biological relevance.
J. Biol. Chem.
272:1956-1964[Abstract/Free Full Text].
|
| 23.
|
Herrera, E.,
M. del Mar Lorenzo,
R. Blasco, and S. N. Isaacs.
1998.
Functional analysis of vaccinia virus B5R protein: essential role in virus envelopment is independent of a large portion of the extracellular domain.
J. Virol.
72:294-302[Abstract/Free Full Text].
|
| 24.
|
Hiller, G.,
H. Eibl, and K. Weber.
1981.
Characterization of intracellular and extracellular vaccinia virus variants: N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine interferes with cytoplasmic virus dissemination and release.
J. Virol.
39:903-913[Abstract/Free Full Text].
|
| 25.
|
Hiller, G., and K. Weber.
1985.
Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment.
J. Virol.
55:651-659[Abstract/Free Full Text].
|
| 26.
|
Hirt, P.,
G. Hiller, and R. Wittek.
1986.
Localization and fine structure of a vaccinia virus gene encoding an envelope antigen.
J. Virol.
58:757-764[Abstract/Free Full Text].
|
| 27.
|
Hollinshead, M.,
A. Vanderplasschen,
G. L. Smith, and D. J. Vaux.
1999.
Vaccinia virus intracellular mature virions contain only one lipid membrane.
J. Virol.
73:1503-1517[Abstract/Free Full Text].
|
| 28.
|
Isaacs, S. N.,
E. J. Wolffe,
L. G. Payne, and B. Moss.
1992.
Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope.
J. Virol.
66:7217-7224[Abstract/Free Full Text].
|
| 29.
|
Katz, E.,
E. J. Wolffe, and B. Moss.
1997.
The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions.
J. Virol.
71:3178-3187[Abstract].
|
| 30.
|
Koonin, E. V.
1996.
A duplicated catalytic motif in a new superfamily of phosphohydrolases and phospholipid synthases that includes poxvirus envelope proteins.
Trends Biochem. Sci.
21:242-243[CrossRef][Medline].
|
| 31.
|
Ktistakis, N. T.,
H. A. Brown,
M. G. Waters,
P. C. Sternweis, and M. G. Roth.
1996.
Evidence that phospholipase D mediates ADP ribosylation factor-dependent formation of Golgi coated vesicles.
J. Cell Biol.
134:295-306[Abstract/Free Full Text].
|
| 32.
|
Lippincott-Schwartz, J.,
L. C. Yuan,
J. S. Bonifacino, and R. D. Klausner.
1989.
Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER.
Cell
56:801-813[CrossRef][Medline].
|
| 33.
|
Lorenzo, M. D.,
E. Herrera,
R. Blasco, and S. N. Isaacs.
1998.
Functional analysis of vaccinia virus B5R protein: role of the cytoplasmic tail.
Virology
252:450-457[CrossRef][Medline].
|
| 34.
|
Lorenzo, M. M.,
I. Galindo,
G. Griffiths, and R. Blasco.
2000.
Intracellular localization of vaccinia virus extracellular enveloped virus envelope proteins individually expressed using a Semliki Forest virus replicon.
J. Virol.
74:10535-10550[Abstract/Free Full Text].
|
| 35.
|
Mathew, E.,
C. M. Sanderson,
M. Hollinshead, and G. L. Smith.
1998.
The extracellular domain of vaccinia virus protein B5R affects plaque phenotype, extracellular enveloped virus release, and intracellular actin tail formation.
J. Virol.
72:2429-2438[Abstract/Free Full Text].
|
| 36.
|
Morgan, C.,
S. Ellison,
H. Rose, and D. Moore.
1954.
Structure and development of viruses observed in the electron microscope. II. Vaccinia and fowl pox viruses.
J. Exp. Med.
100:301-310[Abstract].
|
| 37.
|
Moss, B.
1996.
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
Proc. Natl. Acad. Sci. USA
93:11341-11348[Abstract/Free Full Text].
|
| 38.
|
Moss, B.
1996.
Poxviridae: the viruses and their replication, p. 2637-2671.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 39.
|
Mu, F. T.,
J. M. Callaghan,
O. Steele-Mortimer,
H. Stenmark,
R. G. Parton,
P. L. Campbell,
J. McCluskey,
J. P. Yeo,
E. P. Tock, and B. H. Toh.
1995.
EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine "fingers" and contains a calmodulin-binding IQ motif.
J. Biol. Chem.
270:13503-13511[Abstract/Free Full Text].
|
| 40.
|
Parkinson, J. E., and G. L. Smith.
1994.
Vaccinia virus gene A36R encodes a Mr 43-50 K protein on the surface of extracellular enveloped virus.
Virology
204:376-390[CrossRef][Medline].
|
| 41.
|
Payne, L. G.
1980.
Significance of extracellular virus in the in vitro and in vivo dissemination of vaccinia virus.
J. Gen. Virol.
50:89-100[Abstract/Free Full Text].
|
| 42.
|
Payne, L. G., and E. Norrby.
1976.
Presence of hemagglutinin in the envelope of extracellular vaccinia virus particles.
J. Gen. Virol.
32:63-72[Abstract/Free Full Text].
|
| 43.
|
Ploubidou, A.,
V. Moreau,
K. Ashman,
I. Reckmann,
C. Gonzalez, and M. Way.
2000.
Vaccinia virus infection disrupts microtubule organization and centrosome function.
EMBO J.
19:3932-3944[CrossRef][Medline].
|
| 44.
|
Ponting, C. P., and I. D. Kerr.
1996.
A novel family of phospholipase D homologues that includes phospholipid synthases and putative endonucleases: identification of duplicated repeats and potential active site residues.
Protein Sci.
5:914-922[Medline].
|
| 45.
|
Presley, J. F.,
N. B. Cole,
T. A. Schrer,
K. Hirschberg,
K. J. M. Zaal, and J. Lippincott-Schwartz.
1997.
ER-to-Golgi transport visualized in living cells.
Nature
389:81-85[CrossRef][Medline].
|
| 46.
|
Roper, R.,
E. J. Wolffe,
A. Weisberg, and B. Moss.
1998.
The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus.
J. Virol.
72:4192-4204[Abstract/Free Full Text].
|
| 47.
|
Roper, R. L., and B. Moss.
1999.
Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein.
J. Virol.
73:1108-1117[Abstract/Free Full Text].
|
| 48.
|
Roper, R. L.,
L. G. Payne, and B. Moss.
1996.
Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene.
J. Virol.
70:3753-3762[Abstract].
|
| 49.
|
Rottger, S.,
F. Frischknecht,
I. Reckmann,
G. L. Smith, and M. Way.
1999.
Interactions between vaccinia virus IEV membrane proteins and their roles in IEV assembly and actin tail formation.
J. Virol.
73:2863-2875[Abstract/Free Full Text].
|
| 50.
|
Sanderson, C. M.,
F. Frischknecht,
M. Way,
M. Hollinshead, and G. L. Smith.
1998.
Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low-pH-induced cell-cell fusion.
J. Gen. Virol.
79:1415-1425[Abstract].
|
| 51.
|
Sanderson, C. M.,
M. Hollinshead, and G. L. Smith.
2000.
The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles.
J. Gen. Virol.
81:47-58[Abstract/Free Full Text].
|
| 52.
|
Sandoval, I. V., and O. Bakke.
1994.
Targeting of membrane proteins to endosomes and lysosomes.
Trends Cell Biol.
4:292-297[CrossRef][Medline].
|
| 53.
|
Schmelz, M.,
B. Sodeik,
M. Ericsson,
E. J. Wolffe,
H. Shida,
G. Hiller, and G. Griffiths.
1994.
Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans-Golgi network.
J. Virol.
68:130-147[Abstract/Free Full Text].
|
| 54.
|
Schmutz, C.,
L. Rindisbacher,
M. C. Galmiche, and R. Wittek.
1995.
Biochemical analysis of the major vaccinia virus envelope antigen.
Virology
213:19-27[CrossRef][Medline].
|
| 55.
|
Seaman, M. N. J.
1996.
Phospholipase D in vesicle budding.
Trends Cell Biol.
6:473[CrossRef][Medline].
|
| 56.
|
Simon, J. P.,
I. E. Ivanov,
M. Adesnik, and D. D. Sabatini.
1996.
The production of post-Golgi vesicles requires a protein kinase C-like molecule, but not its phosphorylating activity.
J. Cell Biol.
135:355-370[Abstract/Free Full Text].
|
| 57.
|
Sodeik, B.,
R. W. Doms,
M. Ericsson,
G. Hiller,
C. E. Machamer,
W. van't Hof,
G. van Meer,
B. Moss, and G. Griffiths.
1993.
Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks.
J. Cell Biol.
121:521-541[Abstract/Free Full Text].
|
| 58.
|
Stokes, G. V.
1976.
High-voltage electron microscope study of the release of vaccinia virus from whole cells.
J. Virol.
18:636-643[Abstract/Free Full Text].
|
| 59.
|
Stutchfield, J., and S. Cockcroft.
1993.
Correlation between secretion and phospholipase D activation in differentiated HL60 cells.
Biochem. J.
293:649-655.
|
| 60.
|
Sung, T.-C.,
R. L. Roper,
Y. Zhang,
S. A. Rudge,
R. Temel,
S. M. Hammond,
A. J. Morris,
B. Moss,
J. Engebrecht, and M. A. Frohman.
1997.
Mutagenesis of phospholipase D defines a superfamily including a trans-Golgi viral protein required for poxvirus pathogenicity.
EMBO J.
16:4519-4530[CrossRef][Medline].
|
| 61.
|
Tooze, J.,
M. Hollinshead,
B. Reis,
K. Radsak, and H. Kern.
1993.
Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes.
Eur. J. Cell Biol.
60:163-178[Medline].
|
| 62.
|
Trowbridge, I. S.,
J. F. Collawn, and C. R. Hopkins.
1993.
Signal-dependent membrane protein trafficking in the endocytic pathway.
Annu. Rev. Cell Biol.
9:129-161[CrossRef].
|
| 63.
|
Tsien, R. Y.
1998.
The green fluorescent protein.
Annu. Rev. Biochem.
67:509-544[CrossRef][Medline].
|
| 64.
|
van Eijl, H.,
M. Hollinshead, and G. L. Smith.
2000.
The vaccinia virus A36R protein is a type Ib membrane protein present on intracellular but not extracellular enveloped virus particles.
Virology
271:26-36[CrossRef][Medline].
|
| 65.
|
Ward, B. M., and B. Moss.
2000.
Golgi network targeting and plasma membrane internalization signals in vaccinia virus B5R envelope protein.
J. Virol.
74:3771-3780[Abstract/Free Full Text].
|
| 66.
|
Ward, B. M., and B. Moss.
2001.
Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera.
J. Virol.
75:4802-4813[Abstract/Free Full Text].
|
| 67.
|
Wolffe, E. J.,
S. N. Isaacs, and B. Moss.
1993.
Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination.
J. Virol.
67:4732-4741[Abstract/Free Full Text].
|
| 68.
|
Wolffe, E. J.,
E. Katz,
A. Weisberg, and B. Moss.
1997.
The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus.
J. Virol.
71:3904-3915[Abstract].
|
| 69.
|
Wolffe, E. J.,
D. M. Moore,
P. J. Peters, and B. Moss.
1996.
Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis.
J. Virol.
70:2797-2808[Abstract].
|
| 70.
|
Wolffe, E. J.,
A. Weisberg, and B. Moss.
2001.
The vaccinia virus A33R protein provides a chaperone function for viral membrane localization and tyrosine phosphorylation of the A36R protein.
J. Virol.
75:303-310[Abstract/Free Full Text].
|
| 71.
|
Wolffe, E. J.,
A. S. Weisberg, and B. Moss.
1998.
Role for the vaccinia virus A36R outer envelope protein in the formation of virus-tipped actin-containing microvilli and cell-to-cell virus spread.
Virology
244:20-26[CrossRef][Medline].
|
| 72.
|
Zhang, W. H.,
D. Wilcock, and G. L. Smith.
2000.
Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.
J. Virol.
74:11654-11662[Abstract/Free Full Text].
|
Journal of Virology, August 2001, p. 7528-7542, Vol. 75, No. 16
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.16.7528-7542.2001
This article has been cited by other articles:
-
Tan, J. L., Ueda, N., Mercer, A. A., Fleming, S. B.
(2009). Investigation of orf virus structure and morphogenesis using recombinants expressing FLAG-tagged envelope structural proteins: evidence for wrapped virus particles and egress from infected cells. J. Gen. Virol.
90: 614-625
[Abstract]
[Full Text]
-
Izmailyan, R., Chang, W.
(2008). Vaccinia Virus WR53.5/F14.5 Protein Is a New Component of Intracellular Mature Virus and Is Important for Calcium-Independent Cell Adhesion and Vaccinia Virus Virulence in Mice. J. Virol.
82: 10079-10087
[Abstract]
[Full Text]
-
Perdiguero, B., Lorenzo, M. M., Blasco, R.
(2008). Vaccinia Virus A34 Glycoprotein Determines the Protein Composition of the Extracellular Virus Envelope. J. Virol.
82: 2150-2160
[Abstract]
[Full Text]
-
Perdiguero, B., Blasco, R.
(2006). Interaction between Vaccinia Virus Extracellular Virus Envelope A33 and B5 Glycoproteins.. J. Virol.
80: 8763-8777
[Abstract]
[Full Text]
-
Herrero-Martinez, E., Roberts, K. L., Hollinshead, M., Smith, G. L.
(2005). Vaccinia virus intracellular enveloped virions move to the cell periphery on microtubules in the absence of the A36R protein. J. Gen. Virol.
86: 2961-2968
[Abstract]
[Full Text]
-
Ludlow, M., McQuaid, S., Cosby, S. L., Cattaneo, R., Rima, B. K., Duprex, W. P.
(2005). Measles virus superinfection immunity and receptor redistribution in persistently infected NT2 cells. J. Gen. Virol.
86: 2291-2303
[Abstract]
[Full Text]
-
Carter, G. C., Rodger, G., Murphy, B. J., Law, M., Krauss, O., Hollinshead, M., Smith, G. L.
(2003). Vaccinia virus cores are transported on microtubules. J. Gen. Virol.
84: 2443-2458
[Abstract]
[Full Text]
-
Husain, M., Moss, B.
(2003). Intracellular Trafficking of a Palmitoylated Membrane-Associated Protein Component of Enveloped Vaccinia Virus. J. Virol.
77: 9008-9019
[Abstract]
[Full Text]
-
Smith, G. L., Vanderplasschen, A., Law, M.
(2002). The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol.
83: 2915-2931
[Abstract]
[Full Text]
-
Husain, M., Moss, B.
(2002). Similarities in the Induction of Post-Golgi Vesicles by the Vaccinia Virus F13L Protein and Phospholipase D. J. Virol.
76: 7777-7789
[Abstract]
[Full Text]